Delphi
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Advanced Research Projects Agency for Health (ARPA-H) has issued a Solicitation for the Delphi program, seeking innovative solutions to develop modular, chiplet-based wearable or ingestible biosensors for continuous biological monitoring. This initiative aims to revolutionize biosensor cost and performance, enabling early disease detection, continuous home recovery monitoring, and precision therapy. Proposals are due May 13, 2026, at 5:00 PM ET.
Purpose & Vision
The Delphi program's vision is to empower Americans with a deep understanding of their own bodies through continuous monitoring of biological information like hormones, cytokines, and drug levels. By leveraging chiplets, the program seeks to significantly decrease cost, reduce size, weight, and power (SWaP), and make cutting-edge biosensing capabilities broadly accessible.
Scope of Work
This 54-month, 3-phase program (Phase I: 24 months, Phase II: 18 months, Phase III: 12 months) requires proposers to address four Technical Areas (TAs):
- TA1: Dry Chiplets Unique to Biosensing: Develop ultra-low power management chiplets and secure medical data transmission chiplets, along with common packaging and interconnect strategies.
- TA2: Wet Biosensing Chiplets: Create biology-facing sensors integrated into chiplets for continuous tracking of low-concentration biochemical markers.
- TA3: Biocompatible Encapsulation: Develop encapsulation methods that protect electronics while selectively exposing the sensing interface, ensuring long-term reliability.
- TA4: Human Factors Testing or Clinical Trial: Plan for either non-invasive human factors evaluation or minimally invasive human clinical trials.
Contract & Timeline
- Contract Type: Solicitation, anticipated multiple Other Transaction (OT) Agreements.
- Set-Aside: None specified; open to universities, non-profit organizations, small businesses, and other commercial entities. FFRDCs and government entities are generally prohibited unless possessing unique capabilities.
- Published Date: April 28, 2026.
- Amendment 1 Issued: April 30, 2026.
- Solution Summaries Due: April 8, 2026, 5:00 PM ET (passed).
- Proposals Due: May 13, 2026, 5:00 PM ET.
Submission & Evaluation
This is a two-step process, with Solution Summaries already submitted. Full proposals must address all four TAs and select a track for TA4 (non-invasive or minimally invasive). Proposals must include a company that has designed, fabricated, and sold a microelectronic chip. Evaluation criteria include Overall Scientific and Technical Merit, Proposer's Capabilities and/or Related Experience, Potential Contribution and Relevance, and Assessment of Proposed Cost/Price. Registration in SAM.gov with a valid Unique Entity Identifier (UEI) is required for proposal submission and award.
Contact Information
For inquiries, contact DELPHI ISO at DELPHI@arpa-h.gov.